Kyu-Nam Heo

Mr. Kyu-Nam Heo

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ALAh Young Lee
Ah Young Lee
JJJonghyun Jeong
Jonghyun Jeong
KHKyu-Nam Heo
Kyu-Nam Heo
SPSoyoung Park
Soyoung Park
YAYoung-Mi Ah
Young-Mi Ah
SMSangil Min
Sangil Min
Background: Immunosuppressive therapies are vital for solid organ transplant (SOT) recipients to ensure graft survival, but long-term use can lead to complications. This study aimed to comprehensively evaluate the complications associated with immunosuppressive agents across different types of major SOTs. Methods: In a retrospective cohort study using a national claims database, we analyzed adult SOT recipients who began immunosuppressive therapy from 2007 to 2018. We identified complications such as infections, acute kidney injury, hypertensive emergencies, chronic kidney disease, hypertension, diabetes, dyslipidemia, and osteoporosis. These outcomes were determined through diagnostic codes, medication usage data, and hospital or emergency department visits. Results: Among 30,997 transplants with three-year follow up, complication rates varied by transplant type. Pancreatic transplant recipients had the lowest complication rate (225.9 per 1000 patient-years), while lung transplant recipients experienced the highest rate (823.9 per 1000 patient-years). Serious infections and chronic kidney disease were most common 2 to 6 months post transplant. Other complications, like acute kidney injury, hypertensive emergencies, hypertension, diabetes, dyslipidemia, and osteoporosis, were predominantly observed in the first month. Opportunistic infections peaked between 7 months and 1 year after transplantation. Conclusions: This study emphasizes the varied complications related to immunosuppressive therapy among different SOT recipients, delineating specific timeframes for each complication and maintenance regimen.

15 November 2023 in International Journal of Medical Informatics
Verified
Journal Article
Closed access
TTTam Tran-The
Tam Tran-The
EHEunjeong Heo
Eunjeong Heo
SLSanghee Lim
Sanghee Lim
YSYewon Suh
Yewon Suh
KHKyu-Nam Heo
Kyu-Nam Heo
SJSe Young Jung
Se Young Jung

12 January 2023 in Medicina
Verified
Journal Article
Open access
PDF file
JHJu-Hee Han
Ju-Hee Han
KHKyu-Nam Heo
Kyu-Nam Heo
JHJi Min Han
Ji Min Han
MLMo-Se Lee
Mo-Se Lee
SKSu-Jin Kim
Su-Jin Kim
JLJuyeun Lee
Juyeun Lee
Background and objectives: We aimed to describe medication-related incidents or medication errors (MEs) reported by community pharmacists and analyze the prevalent medications involved. Materials and Methods: We extracted ME reports from databases comprising patient safety incidents reported to the Korean Pharmaceutical Association between January 2013 and June 2021. Medications were analyzed according to the second (therapeutic subgroup) and fifth (chemical substance) levels of the Anatomical Therapeutic Chemical classification. Results: A total of 9046 MEs were identified, most of which were near miss reports (88.3%). Among the errors that reached the patients (521 cases), harmful incidents accounted for 76.8%. Most MEs occurred during prescription (89.5%), while harmful MEs occurred mainly during dispensing (73.3%). In the prescription step, wrong drugs (44.8%), dosing errors (27.0%), and wrong durations (14.0%) were common. Anti-inflammatory and anti-rheumatic products (M01), drugs for acid-related disorders (A02), and antihistamines for systemic use (R06) were the most frequently reported medication classes involved. Harmful incidents were most common for dosing errors (31.0%) and wrong drugs (26.8%) and were common with warfarin, levothyroxine, and glimepiride. Conclusions: The MEs reported by community pharmacists were mainly prescribing errors, most of which were rectified before reaching patients. The prevalent medications involved in harmful errors include anti-diabetic, anti-thrombotic, and anti-inflammatory agents.

BYBo Ram Yang
Bo Ram Yang
KHKyu-Nam Heo
Kyu-Nam Heo
YYYun Mi Yu
Yun Mi Yu
GYGa-Bin Yeom
Ga-Bin Yeom
HCHye Duck Choi
Hye Duck Choi
YAYoung-Mi Ah
Young-Mi Ah
Media has become a major source of information on health and plays a role in the decision-making process on health topics. We aimed to evaluate the association between zolpidem use and media broadcasts that reported the suicide risk. We obtained the data of adult outpatients who have been prescribed zolpidem or other hypnotics from the National Patient Sample database (2015–2017). We evaluated the change in zolpidem or other hypnotic prescription trends based on the prescription rate and average daily prescribed dose before and after July 2016, using interrupted time series analysis. A total of 129,787 adult patients had at least one zolpidem prescription in 3 years. The prescription rate of zolpidem after the broadcast decreased significantly by 0.178% (95% confidence interval (CI): −0.214, −0.142), whereas that of other hypnotic users did not differ from that before the broadcast (−0.020%, 95% CI: −0.088, 0.047). However, the trends in the prescription rate before and after the broadcast did not differ for zolpidem and other hypnotics. Broadcasting medication safety through major public media could have an effect on medication use. After broadcasting about the suicide risk of zolpidem, its overall prescription rate decreased immediately, but the trend was not changed.

4 March 2023 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
SLSuhyun Lee
Suhyun Lee
KHKyu-Nam Heo
Kyu-Nam Heo
MLMee Yeon Lee
Mee Yeon Lee
YAYoung‐Mi Ah
Young‐Mi Ah
JSJaekyu Shin
Jaekyu Shin
JLJuyeun Lee
Juyeun Lee

4 November 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
KHKyu-Nam Heo
Kyu-Nam Heo
JJJonghyun Jeong
Jonghyun Jeong
JSJihoo Shin
Jihoo Shin
JSJaekyu Shin
Jaekyu Shin
HYHan Young Yu
Han Young Yu
JLJuyeun Lee
Juyeun Lee
Background: Current tools for assessing ischemic stroke and bleeding risks in patients with atrial fibrillation focus on warfarin users and initial therapy decisions; however, dynamic models for reassessing these risks in direct oral anticoagulant (DOAC) users are lacking. We aimed to develop a tool that enables the dynamic evaluation of thromboembolic and bleeding risks in patients with atrial fibrillation receiving DOAC therapy. Methods: Using a national claims database, we included 42 450 patients with atrial fibrillation who were newly prescribed DOACs and divided them into development (2018) and temporal‐validation (2019) cohorts. We applied a landmarking approach and developed dynamic prediction models incorporating time‐dependent variables. The Fine–Gray subdistribution hazard model, which accounts for death as a competing risk, was used to derive these models. Results: Dynamic prediction models incorporating time‐dependent variables, such as DOAC adherence, were developed to estimate the 1‐year thromboembolic and major bleeding risks over a 2‐year period following DOAC initiation. The thromboembolic and major bleeding risk prediction models achieved a concordance index of 0.715 (95% CI, 0.701–0.729), and 0.697 (95% CI, 0.682–0.710), respectively. The thromboembolic model outperformed CHA 2 DS 2 ‐VASc (concordance index, 0.664 [95% CI, 0.652–0.678]) by 0.051 (95% CI, 0.038–0.062), and the major bleeding model outperformed HAS‐BLED (concordance index, 0.627 [95% CI, 0.611–0.641]) by 0.070 (95% CI, 0.055–0.084). Calibration plots showed good alignment between the predicted and observed probabilities. Nomograms were constructed for each model to enhance its clinical utility. Conclusions: These dynamic prediction models offer a novel approach for reassessing thromboembolic and major bleeding risks in patients with atrial fibrillation receiving DOACs, demonstrating superior performance compared with existing models. Enabling regular risk updates based on the patient’s current status, these tools support personalized and dynamic risk assessments in clinical practice.